Surrey Heartlands

Joint Formulary & PAD

Riluzole - Motor neurone disease

You are here : Home > Formulary Search > Riluzole - Motor neurone disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :

Documentation

NICE Technology Appraisal
NICE TA20 - Riluzole for Motor Neurone Disease
Shared Care
Riluzole for patients within adult services - National shared care - April 2025
Shared Care
Shared Care Request letter (Specialist to Primary Care Prescriber) - National Shared Care - Appendix 1
Shared Care
Shared Care Agreement Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 2
Shared Care
Shared Care Refusal Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 3

PAD Profile

ChemicalSubstance :
Riluzole
Indication :
Motor neurone disease
Group Name :
Keywords :
amyotrophic lateral sclerosis, ALS, MND
Brand Names Include :
Rilutek, Emylif
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5

Other Indications

Below are listed other indications that Riluzole is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Motor neurone disease.

  • No records returned.

Committee Recommendations (1)

05 Sep 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network recommends the use of riluzole in line with NICE TA20, for the treatment of individuals with the amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease.

Riluzole should be only be initiated by a neurological specialist with expertise in the management of MND, but can be managed in primary care via a shared care agreement with general practitioners, and as such is considered as AMBER on the traffic light system.

PLEASE NOTE: In May 2017, the Prescribing Clinical Network recommended that the branded product Rilutek would be considered BLACK on the traffic light system.